Table 2.

Course of symptoms and chest imaging findings of patients in the minocycline and control groups.

Variable	Minocycline group (n = 12)	Control group (n = 9)	P value
Symptoms in clinical course† (n, %)	12 (100.0%)	9 (100.0%)	1.000
Fever (n, %)	8 (66.7%)	8 (88.9%)	0.338
Dyspnea (n, %)	0	2 (22.2%)	0.171
Cough (n, %)	10 (83.3%)	6 (66.7%)	0.611
Sputum (n, %)	5 (41.7%)	5 (55.6%)	0.670
General malaise (n, %)	8 (66.7%)	6 (66.7%)	1.000
Nasal discharge (n, %)	4 (33.3%)	1 (11.1%)	0.338
Sore throat (n, %)	3 (25.0%)	3 (33.3%)	1.000
Headache (n, %)	5 (41.7%)	2 (22.2%)	0.642
Diarrhea (n, %)	5 (41.7%)	6 (66.7%)	0.387
Low appetite (n, %)	5 (41.7%)	7 (77.8%)	0.184
Taste and smell disorder (n, %)	6 (50.0%)	4 (44.4%)	1.000
Myalgia (n, %)	3 (25.0%)	1 (11.1%)	0.603
Duration of symptoms during hospitalization
Dyspnea, days (median, IQR)	0 (0–0)	0 (0–0)	0.236
Cough, days (median, IQR)	5.0 (2.0–8.0)	7.0 (0–11.0)	0.545
Sputum, days (median, IQR)	0 (0–4.5)	1.0 (0–2.0)	0.971
General malaise, days (median, IQR)	1.0 (0–8.5)	4.0 (0–7.0)	0.836
Nasal discharge, days (median, IQR)	0 (0–1.0)	0 (0–0)	0.067
Sore throat, days (median, IQR)	0 (0–0.5)	0 (0–1.0)	0.640
Headache, days (median, IQR)	0 (0–4.8)	0 (0–0)	0.079
Diarrhea, days (median, IQR)	0 (0–0.3)	1.0 (0–1.0)	0.255
Low appetite, days (median, IQR)	0 (0–7.0)	4.0 (0–7.0)	0.715
Taste and smell disorder, days (median, IQR)	1.5 (0–7.3)	0 (0–4.0)	0.166
Myalgia, days (median, IQR)	0 (0–0.3)	0 (0–0)	0.332
Chest imaging findings in acute phase, infiltrate and/or ground-glass opacity (n, %)	11 (91.7%)	9 (100.0%)	1.000
Chest imaging findings in convalescent phase
Imaging tests available (n, %)	5 (41.7%)	4 (44.4%)	1.000
Complete improvement (n, %)	3/5 (60.0%)	1/4 (25.0%)	0.524
Partial improvement (n, %)	2/5 (40.0%)	3/4 (75.0%)	0.524

†Symptoms at onset and during hospitalization.

*Values of P < 0.05 were deemed significant.

IQR, interquartile range.